Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
Links to related guidelines are provided separately. (See "Society guideline links: Candidiasis" and "Society guideline links: Aspergillosis" and "Society guideline links: Pneumocystis pneumonia in patients without HIV".)
International
●International Pediatric Fever and Neutropenia Guideline Panel: Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients, update (2023)
●International Society for Heart and Lung Transplantation (ISHLT): Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients – Executive summary, 2015 (published 2016)
●Center for International Blood and Marrow Transplant Research (CIBMTR), National Marrow Donor Program (NMDP), European Blood and Marrow Transplant Group (EBMT), American Society for Blood and Marrow Transplant (ASBMT), Canadian Blood and Marrow Transplant Group (CBMTG), Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), Association of Medical Microbiology and Infectious Diseases (AMMI), the Center for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA): Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients – A global perspective (RETIRED; published 2009)
United States
●American Academy of Pediatrics (AAP): Red Book – Antimicrobial agents and related therapy (2021)
●American Society of Transplantation (AST): Guidelines on emerging fungal infections in solid organ transplant recipient (2019)
●American Thoracic Society (ATS): Official clinical practice guideline on microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice (2019)
●American Society of Clinical Oncology (ASCO) and Infectious Diseases Society of America (IDSA): Clinical practice guideline on antimicrobial prophylaxis for adult patients with cancer-related immunosuppression, update (2018)
●Clinical Pharmacogenetics Implementation Consortium (CPIC): Guideline for voriconazole and CYP2C19 (2016)
●ATS: Official statement on the treatment of fungal infections in adult pulmonary and critical care patients (2011)
Europe
●European Conference on Infections in Leukaemia (ECIL): 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation (published 2021)
●ECIL: European guidelines for primary antifungal prophylaxis in adult haematology patients – Summary of the updated recommendations (2018)
●ECIL: Guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2017)
●European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM): 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases (published 2014)
●ECIL: Recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients (2012)
United Kingdom
●British Society for Medical Mycology (BSMM): Best practice recommendations for the diagnosis of serious fungal diseases (2015)
Australia–New Zealand
●Royal Australasian College of Physicians (RACP): Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation (2021)
●RACP: Consensus guidelines for antifungal stewardship, surveillance and infection prevention (2021)
●RACP: Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting (2021)
●RACP: Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes inpatients with haematological malignancy and haemopoietic stem cell transplant recipients (2021)
●RACP: Consensus guidelines for the diagnosis and management of cryptococcosis and rare yeast infections in the haematology/oncology setting (2021)
●RACP: Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than Aspergillus in the haematology/oncology setting (2021)
